Cancer Patients Overlooked in COVID-19 Vaccine Rollout

Cancer Patients Overlooked in COVID-19 Vaccine Rollout

CHICAGO PRNewswire -- Almost two-thirds of U.S. states
failed to prioritize cancer patients for COVID-19 vaccinations, despite recommendations from the Centers for Disease Control and Prevention (CDC), according to a study being presented today at the annual meeting of the Radiological Society of North America (RSNA).

Cancer patients are particularly vulnerable to the effects of COVID-19. Both the disease and treatments like chemotherapy and
radiation therapy can leave their immune systems in a weakened state.

Available vaccines are highly effective, but initial supply limitations
forced the CDC’s Advisory Committee on Immunization Practices to make difficult patient prioritization decisions. People ages 16 to 64 with high-risk conditions were grouped into the final part of the first phase, along with people ages 65 to 74. However, this group
encompassed 129 million people nationally, leading many states to
sub-prioritize.

For the new study, researchers sought to determine the proportion
of states that elected to follow CDC recommendations. They identified every states’ COVID vaccination webpage through keyword-based internet search and set out to identify information about vaccination for cancer patients.

While 43 states included cancer among criteria for vaccination,
only 17 gave patients with cancer the same immunization priority as
patients aged 65 to 74, and a mere eight precisely defined a qualifying cancer diagnosis.

“Although the CDC recommended that all states consider people
with significant medical conditions to have equal vaccination priority
with people over the age of 65, we found that nearly two-thirds of
states did not give equal vaccination priority to patients with cancer,”
said study lead author Rahul Prasad, M.D., from The Ohio State
University Comprehensive Cancer Center in Columbus, Ohio.

Forty-two states did not clearly define the criteria for cancer patients
to receive priority vaccination.This lack of clarity is problematic,
Dr. Prasad noted, due to considerable variation within the cancer patient population.

“You could have someone diagnosed with breast cancer at age 40
who is now 55, in remission, and wondering if they’re eligible,” Dr.
Prasad said. “On the other side of the spectrum, someone newly diagnosed with low-risk prostate cancer may not be particularly immunocompromised if they haven’t started treatment yet.”

Of the eight states that defined a qualifying cancer diagnosis for
vaccine prioritization, six limited it to patients currently receiving treatment.

Dr. Prasad said the shortfall in the number of states that followed
the CDC recommendations is partly due to attempts at streamlining
vaccination efforts.

“I don’t think anyone intended to push people to the back of the
line,” he said. “The efforts were well intentioned, but what ended
up happening was that the CDC governing bodies’ definition of
high-risk medical conditions was too broad.”

Early in the fall, the CDC approved a booster shot for seniors
and high-risk individuals. Dr. Prasad said that these booster shots
offer an opportunity to better mitigate disparities in vaccine access.
“It’s especially critical this time around to make sure these most
at-risk people are getting their boosters in a timely fashion,” Dr.
Prasad said.

Joshua Palmer, M.D., is the co-author.

RSNA is an association of radiologists, radiation oncologists,
medical physicists and related scientists promoting excellence in
patient care and health care delivery through education, research
and technologic innovation. The Society is based in Oak Brook,
Illinois. (RSNA.org)

Latest Stories

Latest Podcast

STARR Community Services International, Inc.